Last reviewed · How we verify
Placebo(for Limaprost)
Placebo is an inert substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo(for Limaprost) |
|---|---|
| Sponsor | Yungjin Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo serves as a control comparator in clinical trials and has no direct molecular or therapeutic mechanism of action. Any observed effects are attributable to placebo response (psychological and contextual factors) rather than pharmacological activity. In the context of this trial, placebo was used as a comparator arm to evaluate the efficacy of Limaprost.
Approved indications
Common side effects
Key clinical trials
- Effect of Limaprost in Combination With Transforaminal Epidural Steroid Injection (NA)
- The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy (PHASE3)
- A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo(for Limaprost) CI brief — competitive landscape report
- Placebo(for Limaprost) updates RSS · CI watch RSS
- Yungjin Pharm. Co., Ltd. portfolio CI